socio-economic benefits

R&D

It has been estimated that 12% of the UK population suffer from irritable bowel syndrome (IBS), an umbrella term that describes a bro

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.